🚀 VC round data is live in beta, check it out!
Vita Life Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vita Life Sciences and similar public comparables like Venture Life Group, Biome Australia, FitLife Brands, Hofseth BioCare and more.
Vita Life Sciences Overview
About Vita Life Sciences
Vita Life Sciences Ltd is an Australian based pharmaceutical and healthcare company involved in formulating, packaging, sales, and distribution of vitamins and supplements. The company produces a wide range of premium supplements, vitamins, minerals, herbs and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, Herbs of Gold brands throughout Asia-Pacific region. The company has four reportable segments which include The Australia segment comprises of sale of Herbs of Gold range in Australia and exports into China. The Singapore and Malaysia segment, comprise of Vitahealth and Herbs of Gold range in both countries The other market segment comprises of Vitahealth ranges.
Founded
1986
HQ
Employees
N/A
Website
Financials (FY)
EV
$80M
Vita Life Sciences Financials
Vita Life Sciences reported last fiscal year revenue of $56M and EBITDA of $9M.
In the same fiscal year, Vita Life Sciences generated $33M in gross profit, $9M in EBITDA, and $6M in net income.
Revenue (LTM)
Vita Life Sciences P&L
In the most recent fiscal year, Vita Life Sciences reported revenue of $56M and EBITDA of $9M.
Vita Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $56M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $33M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 59% | XXX | XXX | XXX |
| EBITDA | — | XXX | $9M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 15% | XXX | XXX | XXX |
| Net Profit | — | XXX | $6M | XXX | XXX | XXX |
| Net Margin | — | XXX | 11% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Vita Life Sciences Stock Performance
Vita Life Sciences has current market cap of $99M, and enterprise value of $80M.
Market Cap Evolution
Vita Life Sciences' stock price is $1.78.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $80M | $99M | -1.1% | XXX | XXX | XXX | $0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVita Life Sciences Valuation Multiples
Vita Life Sciences trades at 1.4x EV/Revenue multiple, and 8.4x EV/EBITDA.
EV / Revenue (LTM)
Vita Life Sciences Financial Valuation Multiples
As of March 20, 2026, Vita Life Sciences has market cap of $99M and EV of $80M.
Equity research analysts estimate Vita Life Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vita Life Sciences has a P/E ratio of 16.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $99M | XXX | $99M | XXX | XXX | XXX |
| EV (current) | $80M | XXX | $80M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 8.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 9.7x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.4x | XXX | XXX | XXX |
| P/E | — | XXX | 16.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 19.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vita Life Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Vita Life Sciences Margins & Growth Rates
Vita Life Sciences' revenue in the last fiscal year grew by 7%.
Vita Life Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 3% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Vita Life Sciences Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Venture Life Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Biome Australia | XXX | XXX | XXX | XXX | XXX | XXX |
| FitLife Brands | XXX | XXX | XXX | XXX | XXX | XXX |
| Hofseth BioCare | XXX | XXX | XXX | XXX | XXX | XXX |
| Enzymatica | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vita Life Sciences M&A Activity
Vita Life Sciences acquired XXX companies to date.
Last acquisition by Vita Life Sciences was on XXXXXXXX, XXXXX. Vita Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Vita Life Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVita Life Sciences Investment Activity
Vita Life Sciences invested in XXX companies to date.
Vita Life Sciences made its latest investment on XXXXXXXX, XXXXX. Vita Life Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Vita Life Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vita Life Sciences
| When was Vita Life Sciences founded? | Vita Life Sciences was founded in 1986. |
| Where is Vita Life Sciences headquartered? | Vita Life Sciences is headquartered in Australia. |
| Is Vita Life Sciences publicly listed? | Yes, Vita Life Sciences is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Vita Life Sciences? | Vita Life Sciences trades under VLS ticker. |
| When did Vita Life Sciences go public? | Vita Life Sciences went public in 2007. |
| Who are competitors of Vita Life Sciences? | Vita Life Sciences main competitors are Venture Life Group, Biome Australia, FitLife Brands, Hofseth BioCare. |
| What is the current market cap of Vita Life Sciences? | Vita Life Sciences' current market cap is $99M. |
| What is the current revenue of Vita Life Sciences? | Vita Life Sciences' last fiscal year revenue is $56M. |
| What is the current EV/Revenue multiple of Vita Life Sciences? | Current revenue multiple of Vita Life Sciences is 1.4x. |
| Is Vita Life Sciences profitable? | No, Vita Life Sciences is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.